黑色素瘤
获批药物
免疫检查点抑制剂
抗血管生成 [2]
- VEGF
- Bevacizumab
- VEGFR
- Lenvatinib
- Anlotinib dihydrochloride
- Nintedanib
- Cabozantinib malate
- Axitinib
- Sunitinib malate
- Sorafenib tosylate
- Apatinib mesylate
- Vorolanib
- FGFR
- Lenvatinib
- Golvatinib
- MMPs
- Marimastat
- Doxycycline
靶向疗法 (A)
- BRAF
- Encorafenib
- Exarafenib
- Tubulin
- Nab-Paclitaxel
- Paclitaxel
- Vindesine sulfate
- Vincristine sulfate
- Verubulin hydrochloride
- Patupilone
- JAK1/2
- Ruxolitinib
靶向疗法 (B)
- MEK1/2
- Selumetinib
- Binimetinib
- Cobimetinib
- Trametinib DMSO solvate
- Mirdametinib
- Pimasertib
- TAK-733
- GDC-0623
- ERK1/2
- ASN007
- Temuterkib
- Ulixertinib
- Ravoxertinib
- 4-1BB/CD137
- Urelumab
- Utomilumab
干细胞标志物 [2]
- KLF4
- APTO-253
激酶抑制剂 [3]
